Skip to content
Vgmoph Logo

Archives

VGMorph part of the event’s panel at British Chamber of Commerce Germany AI summit

The VGMorph managing directors provided interesting insights into how artificial intelligence is used in their company and how it enables processes that benefit patients.

VGMorph at AI & blockchain

Artificial intelligence & blockchain – buzzwords or real game changers?

VGMorph now member at the ZENIT network

VGM: Fully automated AI-assisted diagnostics of brain MRI

MRI-based morphometric structural changes correlate with histopathology in experimental autoimmune encephalomyelitis

MRI

Magnetic resonance imaging (MRI) and neurohistopathology are important correlates for evaluation of disease progression in multiple sclerosis (MS).

VGMorph qualified for ‘Successful R & I in Europe’

Successful R & I in Europe

We are delighted to have qualified as VGMorph for the ‘Successful R & I in Europe’ meeting in Düsseldorf.

Participation 2. Startup Night in Frankfurt on March 27, 2025

We are very happy to have been part of the 2nd Startup Night in Frankfurt am Main on March 27, 2025

Venous Diameter Changes in Chronic Active Multiple Sclerosis Lesions

To investigate the temporal evolution of venous diameter in chronic active and nonenhancing shrinking multiple sclerosis (MS) lesions in a longitudinal magnetic resonance imaging (MRI) study including susceptibility‐weighted images (SWI).

Successful participation in the innovation competition “AI for SMEs” 2020

aktuell: Innovationswettbewerb KI für KMU

Awardee of the innovation competition ‘AI for SMEs’ Best Practice Projects: “How medium-sized companies benefit from artificial intelligence”.

Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study

We performed voxel-guided morphometry (VGM) investigating the mechanisms of brain atrophy in multiple sclerosis (MS) related to focal lesions.

Mobilisation of hematopoietic CD34+ precursor cells in patients with acute stroke is safe–results of an open-labeled non randomized phase I/II trial

Regenerative strategies in the treatment of acute stroke may have great potential.

Next →